

PHARMACOLOGY-III
UNIT-IV
TOPIC: IMMUNOSUPPRESSANT



Centurion
UNIVERSITY

Shaping Lives...
Empowering Communities...

Prepared By
Sucharita Babu
Assistant Professor
School of Pharmacy and Life Sciences,
Centurion University of Technology and Management

IMMUNOSUPPRESSANT DRUGS

These are drugs which inhibit cellular /humoral or both immune response and have their major use in organ transplantation and autoimmune diseases. The drugs are:

- 1 . Calcineurin inhibitors (Specific T-cell inhibitors) Cyclosporine (Ciclosporin), Tacrolimus
 2. Antiproliferative drugs (Cytotoxic drugs) Azathioprine, Cyclophosphamide, Methotrexate, Chlorambucil, Mycophenolate mofetil (MMF)
 3. Glucocorticoids: Prednisolone and others
 4. Antibodies: Muromonab CD3, Antithymocyte globulin (ATG), Rho (D) immunoglobulin
- Calcineurin inhibitors (Specific T-cell inhibitors)

A. Cyclosporine

Cyclosporine [sye-kloe-SPOR-een] (CsA) is a lipophilic cyclic polypeptide composed of 11 amino acids (several are methylated on the peptidyl nitrogen). The drug is extracted from a soil fungus. CsA is used to prevent rejection of kidney, liver, and cardiac allogeneic transplants.

Mechanism of action: Cyclosporine preferentially suppresses cell-mediated immune reactions, whereas humoral immunity is affected to a far lesser extent. After diffusing into the T cell, CsA binds to a cyclophilin (more generally called an immunophilin) to form a complex that binds to calcineurin. The latter is responsible for dephosphorylating NFATc (cytosolic Nuclear Factor of Activated T cells). The CsA-calcineurin complex cannot perform this reaction; thus, NFATc cannot enter the nucleus to promote the reactions that are required for the synthesis of a number of cytokines, including IL-2.

Pharmacokinetics:

Cyclosporine may be given either orally or by intravenous infusion.

Oral absorption is variable. Interpatient variability may be due to metabolism by a cytochrome P450 (CYP3A4) in the gastrointestinal tract, where the drug is metabolized. About 50 percent of the drug is associated with the blood fraction

Adverse effects:

Many of the adverse effects caused by CsA are dose dependent; therefore, it is important to monitor blood levels of the drug. Nephrotoxicity is the most common and important adverse effect of CsA. It is therefore critical to monitor kidney function.

B. Tacrolimu

Tacrolimus (TAC, originally called FK506) is a macrolide that is isolated from a soil fungus.

TAC is approved for the prevention of rejection of liver and kidney transplants and is given with a corticosteroids and/or an antimetabolite.

This drug has found favor over CsA, not only because of its potency and decreased episodes of rejection but also because lower doses of corticosteroids can be used, thus reducing the

likelihood of steroid-associated adverse effects. An ointment preparation has been approved for moderate to severe atopic dermatitis that does not respond to conventional therapies.

Immunosuppressive Antimetabolites

Immunosuppressive antimetabolite agents are generally used in combination with corticosteroids, and the calcineurin inhibitors, CsA and TAC.

A. Azathioprine

Azathioprine [ay-za-THYE-oh-preen] was the first agent to achieve widespread use in organ transplantation. It is a prodrug that is converted first to 6-mercaptopurine (6-MP) and then to the corresponding nucleotide, thioinosinic acid. The immunosuppressive effects of azathioprine are due to this nucleotide analog. Because of their rapid proliferation in the immune response and their dependence on the de novo synthesis of purines required for cell division, lymphocytes are predominantly affected by the cytotoxic effects of azathioprine. [Its major nonimmune toxicity is bone marrow suppression. Concomitant use with angiotensin-converting enzyme inhibitors or cotrimoxazole in renal transplant patients can lead to an exaggerated leukopenic response.

Immunosuppressant antibodies:

Muromonab CD3 It is a murine monoclonal antibody against the CD3 glycoprotein located near to the T cell receptor on helper T cells. Binding of muromonab CD3 to the CD3 antigen obstructs the binding of MHC II-antigen complex to the T cell receptor: antigen recognition is interfered, so that participation of T cells in the immune response is prevented and T cells rapidly disappear from circulation leading to an immune blocked state.

Mechanism of action:

Binding to the CD3 protein results in a disruption of T-lymphocyte function, because access of antigen to the recognition site is blocked. Circulating T cells are depleted; thus, their participation in the immune response is decreased.

Because muromonab-CD3 recognizes only one antigenic site, the immunosuppression is less broad than that seen with the polyclonal antibodies. T cells usually return to normal within 48 hours of discontinuation of therapy.

Muromonab CD3 has been used as induction therapy together with corticosteroids and azathioprine with delayed use of cyclosporine in 'sequential regimen' for organ transplantation. This serves to postpone potential nephro- and hepatotoxicity of cyclosporine.